Azathioprine: Difference between revisions

(hepatic dosing)
 
(20 intermediate revisions by 8 users not shown)
Line 1: Line 1:
==Administration==
==Administration==
*Type: immunosuppressant
*Type: immunosuppressant
*Dosage Forms: 50
*Dosage Forms: tablet, powder for injection (IV form unavailable in US)
*Routes of Administration: PO (IV form unavailable in US)
*Dosage Strengths: tablet: 50, 75, 100mg; powder for injection: 100mg/vial
*Routes of Administration: PO, IV (unavailable in US)
*Common Trade Names: Azasan, Imuran
*Common Trade Names: Azasan, Imuran


==Adult Dosing==
==Adult Dosing==
===Kidney transplant rejection prophylaxis===
===Kidney transplant rejection prophylaxis===
*1-3 mg/kg PO qd
*1-3mg/kg PO QD
*Start: 3-5 mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary
*Start: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary


===Rheumatoid arthritis, severe===
===[[Rheumatoid arthritis]], severe===
*1-2.5 mg/kg/day PO divided qd-bid
*1-2.5mg/kg/day PO divided QD-bid
*Start: 1 mg/kg/day PO divided qd-bid; Max: 2.5 mg/kg/day; Info: after 6-8wk may incr. 0.5 mg/kg/day q4wk
*Start: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk


===Crohns Disease===
===Crohns Disease===
*100-250 mg PO qd
*100-250mg PO QD
*Start: 50 mg PO qd; Max: 2.5 mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects
*Start: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects


===Ulcerative colitis===
===Ulcerative colitis===
*100-250 mg PO qd
*100-250mg PO QD
*Start: 50 mg PO qd; Max: 2.5 mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects
*Start: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects


==Pediatric Dosing==
==Pediatric Dosing==
===Kidney transplant rejection prophylaxis===
===Kidney transplant rejection prophylaxis===
*1-3 mg/kg PO qd
*1-3mg/kg PO QD
*Start: 3-5 mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary
*Start: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary


===Juvenile idiopathic arthritis, severe===
===Juvenile idiopathic arthritis, severe===
*1-2.5 mg/kg/day PO divided qd-bid
*1-2.5mg/kg/day PO divided QD-bid
*Start: 1 mg/kg/day PO divided qd-bid; Max: 2.5 mg/kg/day; Info: after 6-8wk may incr. 0.5 mg/kg/day q4wk
*Start: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Pregnancy Category D
*[[Lactation risk categories|Lactation risk]]:
*[[Lactation risk categories|Lactation risk]]: possibly unsafe
===Renal Dosing===
===Renal Dosing===
*Adult: CrCl 10-50: decr. dose 25%; CrCl <10: decr. dose 50%; HD: give 0.25 mg/kg supplement; PD: not defined
*Adult: CrCl 10-50: decrease dose 25%; CrCl <10: decrease dose 50%; HD: give 0.25mg/kg supplement; PD: not defined
*Pediatric: CrCl 10-50: decr. dose 25% or give q36h; CrCl <10: decr. dose 50% or give q48h; HD: give supplement; PD: not defined
*Pediatric: CrCl 10-50: decrease dose 25% or give q36h; CrCl <10: decrease dose 50% or give q48h; HD: give supplement; PD: not defined


===Hepatic Dosing===
===Hepatic Dosing===
Line 44: Line 45:
==Contraindications==
==Contraindications==
*Allergy to class/drug
*Allergy to class/drug
*pregnancy (RA use)
*caution if renal impairment
*caution if prior alkylating agents


==Adverse Reactions==
==Adverse Reactions==
===Serious===
===Serious===
*leukopenia
*thrombocytopenia
*anemia
*myelosuppression
*immunosuppression
*infection
*PML
*GI hypersensitivity reaction
*pancreatitis
*hepatotoxicity
*hepatic veno-occlusive disease
*lymphoma
*malignancy
*acute febrile neutrophilic dermatosis


===Common===
===Common===
*leukopenia
*thrombocytopenia
*anemia
*infection
*nausea
*vomiting
*anorexia
*diarrhea
*ALT, AST elevated
*malaise
*myalgia
*fever
*rash
*malignancy


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 5 hours
*Metabolism:  
*Metabolism: liver extensively, erythrocytes; CYP450
*Excretion:  
*Excretion: bile, urine (1-2% unchanged)


==Mechanism of Action==
==Mechanism of Action==
Acts as a prodrug for mercaptopurine, inhibiting an enzyme required for the synthesis of DNA. Thus, it most strongly affects proliferating cells, such as the T cells and B cells of the immune system


==Comments==
==Comments==


==See Also==
==See Also==
*[[Transplant complications]]


==References==
==References==
*A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157-1163. [PubMed 8229026]
*American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, “Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis,” Arthritis Rheum, 1996, 39(5):723-31. [PubMed 8639168]
*Astey AV, Wakelin S, and Reynolds NJ, “Guidelines for Prescribing Azathioprine in Dermatology,” Br J Dermatol, 2004, 151(6):1123-32. [PubMed 15606506]
*Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013;7(12):e623-e629. doi: 10.1016/j.crohns.2013.04.020. [PubMed 23810678]
*Arnold DM, Nazi I, Santos A, et al, “Combination Immunosuppressant Therapy for Patients With Chronic Refractory Immune Thrombocytopenic Purpura,” Blood, 2010, 115(1):29-31. [PubMed 19897578]
*Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 177.
*Azasan (azathioprine) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; March 2019.
*Azathioprine injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; August 2015.
*Baum D, Bernstein D, Starnes VA, et al, “Pediatric Heart Transplantation at Stanford: Results of a 15-Year Experience,” Pediatrics, 1991, 88(2):203-14. [PubMed 1861916]
*Beissert S, Werfel T, Frieling U, et al, "A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus," Arch Dermatol, 2006, 142(11):1447-54. [PubMed 17116835]
<references/>
<references/>
[[Category:Drugs]]
[[Category:Pharmacology]]
epocrates

Latest revision as of 19:46, 8 March 2021

Administration

  • Type: immunosuppressant
  • Dosage Forms: tablet, powder for injection (IV form unavailable in US)
  • Dosage Strengths: tablet: 50, 75, 100mg; powder for injection: 100mg/vial
  • Routes of Administration: PO, IV (unavailable in US)
  • Common Trade Names: Azasan, Imuran

Adult Dosing

Kidney transplant rejection prophylaxis

  • 1-3mg/kg PO QD
  • Start: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary

Rheumatoid arthritis, severe

  • 1-2.5mg/kg/day PO divided QD-bid
  • Start: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk

Crohns Disease

  • 100-250mg PO QD
  • Start: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects

Ulcerative colitis

  • 100-250mg PO QD
  • Start: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects

Pediatric Dosing

Kidney transplant rejection prophylaxis

  • 1-3mg/kg PO QD
  • Start: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary

Juvenile idiopathic arthritis, severe

  • 1-2.5mg/kg/day PO divided QD-bid
  • Start: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk

Special Populations

Renal Dosing

  • Adult: CrCl 10-50: decrease dose 25%; CrCl <10: decrease dose 50%; HD: give 0.25mg/kg supplement; PD: not defined
  • Pediatric: CrCl 10-50: decrease dose 25% or give q36h; CrCl <10: decrease dose 50% or give q48h; HD: give supplement; PD: not defined

Hepatic Dosing

  • Adult: not defined; caution advised
  • Pediatric: not defined; caution advised

Contraindications

  • Allergy to class/drug
  • pregnancy (RA use)
  • caution if renal impairment
  • caution if prior alkylating agents

Adverse Reactions

Serious

  • leukopenia
  • thrombocytopenia
  • anemia
  • myelosuppression
  • immunosuppression
  • infection
  • PML
  • GI hypersensitivity reaction
  • pancreatitis
  • hepatotoxicity
  • hepatic veno-occlusive disease
  • lymphoma
  • malignancy
  • acute febrile neutrophilic dermatosis

Common

  • leukopenia
  • thrombocytopenia
  • anemia
  • infection
  • nausea
  • vomiting
  • anorexia
  • diarrhea
  • ALT, AST elevated
  • malaise
  • myalgia
  • fever
  • rash
  • malignancy

Pharmacology

  • Half-life: 5 hours
  • Metabolism: liver extensively, erythrocytes; CYP450
  • Excretion: bile, urine (1-2% unchanged)

Mechanism of Action

Acts as a prodrug for mercaptopurine, inhibiting an enzyme required for the synthesis of DNA. Thus, it most strongly affects proliferating cells, such as the T cells and B cells of the immune system

Comments

See Also

References

  • A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157-1163. [PubMed 8229026]
  • American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, “Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis,” Arthritis Rheum, 1996, 39(5):723-31. [PubMed 8639168]
  • Astey AV, Wakelin S, and Reynolds NJ, “Guidelines for Prescribing Azathioprine in Dermatology,” Br J Dermatol, 2004, 151(6):1123-32. [PubMed 15606506]
  • Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013;7(12):e623-e629. doi: 10.1016/j.crohns.2013.04.020. [PubMed 23810678]
  • Arnold DM, Nazi I, Santos A, et al, “Combination Immunosuppressant Therapy for Patients With Chronic Refractory Immune Thrombocytopenic Purpura,” Blood, 2010, 115(1):29-31. [PubMed 19897578]
  • Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 177.
  • Azasan (azathioprine) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; March 2019.
  • Azathioprine injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; August 2015.
  • Baum D, Bernstein D, Starnes VA, et al, “Pediatric Heart Transplantation at Stanford: Results of a 15-Year Experience,” Pediatrics, 1991, 88(2):203-14. [PubMed 1861916]
  • Beissert S, Werfel T, Frieling U, et al, "A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus," Arch Dermatol, 2006, 142(11):1447-54. [PubMed 17116835]


epocrates